Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03400332 |
TitleBMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究 | 阶段
第二阶段
|
Date Added 2018-01-17 |
地点
Arkansas, United States
California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States 澳大利亚 比利时 加拿大 法国 德国 意大利 波兰 西班牙 瑞典 瑞士 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BMS-986253, Ipilimumab, Nivolumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06322693 |
TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | 阶段
第 1 阶段
|
Date Added 2024-03-21 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 大韩民国 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03217747 |
TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | 阶段
Phase 1, Phase 2
|
Date Added 2017-07-14 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio |
标签
MSS/ MMRp
|
| NCT ID NCT05141721 |
TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-12-02 |
地点
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT04104776 |
TitleCPI-0209 对晚期实体瘤和淋巴瘤患者的研究 | 阶段
第 1 阶段
|
Date Added 2019-09-26 |
地点
Georgia, United States
Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States Washington, United States 法国 意大利 大韩民国 波兰 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
CPI-0209, CPI-0209 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05019534 |
TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2021-08-25 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf] |
标签
MSS/ MMRp
|
| NCT ID NCT03981146 |
TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | 阶段
第二阶段
|
Date Added 2019-06-10 |
地点
英国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nivolumab, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT04973163 |
Title测试不同剂量的 BI 1823911 单独或与其他药物联合用于不同类型的 KRAS 基因突变晚期癌症患者的研究 | 阶段
第 1 阶段
|
Date Added 2021-07-22 |
地点
Texas, United States
比利时 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BI 1701963, BI 1823911, Midazolam |
标签
MSS/ MMRp
|
| NCT ID NCT03313778 |
TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors | 阶段
第 1 阶段
|
Date Added 2017-10-18 |
地点
Arizona, United States
California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States 澳大利亚 日本 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
mRNA-4157, Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT05308446 |
TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | 阶段
第二阶段
|
Date Added 2022-04-04 |
地点
Arizona, United States
California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States 波多黎各 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo |
标签
MSS/ MMRp
|
